April 13, 2022
Basilea Reports Preclinical Data on Oncology Drug Candidates BAL0891, Derazantinib and Lisavanbulin at AACR Annual Meeting
Basilea Pharmaceutica Ltd. has reported that promising preclinical data on the anti-cancer activity of its three oncology drug candidates, BAL0891, derazantinib and lisavanbulin, have been presented at the Annual Meeting of the American Association for Cancer Research (AACR) that took place April 8-13, 2022, in New Orleans, USA.